Strive Compounding Pharmacy has filed a federal antitrust lawsuit against Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and restrict patient access to lawful compounded GLP-1 medications.
The complaint, filed on January 14, 2026, in the United States District Court for the Western District of Texas, alleges that the pharmaceutical manufacturers used their dominant market positions to undermine the compounding pharmacy industry by discouraging providers, telehealth platforms, and patients from prescribing and accessing compounded GLP-1 medications.
GLP-1 receptor agonists are widely prescribed for metabolic disease and weight management. When commercial products are unavailable or clinically unsuitable, compounding pharmacies may prepare customized formulations under federal and state regulatory oversight, allowing prescribing decisions to remain between physicians and patients.
Compounding pharmacies serve a lawful and established role within the U.S. healthcare system by preparing customized medications for patients whose needs cannot be met by mass-produced drugs or during periods of drug shortage.
“For us, this is more than just a business dispute; it’s a fight for the right of every patient to have access to the medicine their doctor prescribes, at a price that isn’t dictated by a monopoly,” said Nate Hill, Co-Founder and CEO of Strive Compounding Pharmacy.l
“We are standing up to ensure that medical judgment stays between a doctor and their patient, not a pharmaceutical executive and a balance sheet. Fair competition is essential to this industry and the broader economy. Without it, access vanishes and prices rise. By filing this lawsuit, we are protecting a lawful industry that millions of Americans rely on.”
Strive is represented by BakerHostetler. The case is Strive Specialties Inc. v. Eli Lilly & Co. et al., filed in the United States District Court for the Western District of Texas.
The full complaint is available at: https://www.strivepharmacy.com/antitrustlawsuit
